Lilly's Mounjaro and Zepbound Sales Surge, Widening Gap Over Novo
📊 NVO — Piyasa Yorumu
▼ down · 65%The headline indicates that Lilly's robust sales performance has weakened Novo Nordisk's competitive position. Technical indicators also support this bearish outlook, with the stock falling 10.9% over the last 24 hours and an RSI of 39.8 reflecting weak momentum. The MACD is below the signal line and in negative territory, suggesting that the short-term downtrend may continue. The price has closed below the SMA20 and SMA50, which are likely to act as resistance levels. However, as the stock approaches oversold conditions, some technical rebound is possible, so the confidence level is maintained at moderate.
📊 LLY — Piyasa Yorumu
▲ up · 65%The headline highlights that Eli Lilly's robust increase in sales of Mounjaro and Zepbound has widened its competitive advantage over Novo. This should be viewed as a positive development supporting the company's core growth story. On the technical indicators, the RSI at 61.6 is not in overbought territory, and while the MACD remains negative, it is approaching the signal line, suggesting potential improvement in momentum. The price is trading above the 20-day SMA and near the 50-day SMA, offering potential for a short-term recovery. However, it should be noted that the news may already be priced in, and upside movement could be limited due to overall market uncertainty.